Compare Amylx Pharmaceuticals Inc (AMLX) vs Atmos Energy Corporation (ATO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Atmos Energy Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Atmos Energy Corporation trades at $168.76 (market cap $28.38B). The key difference: Atmos Energy Corporation is far larger — about 11.2× Amylx Pharmaceuticals Inc's market cap, and Atmos Energy Corporation pays a 2.38% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | ATO | |
|---|---|---|
Market Cap | $2.53B | $28.38B |
Sector | Health | Utilities |
52-Week High | $24.19 | $192.25 |
52-Week Low | $7.82 | $162.44 |
Enterprise Value | $2.28B | $38.18B |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
Atmos Energy (ATO) trades at $170.19, down 1.04% today, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $1.43, beating expectations by 5.9%, and maintains strong fundamentals with 28.5% net income margin and $4.70B revenue. Recent board appointments and dividend declarations highlight corporate stability, while analyst consensus targets $190.57 with 45% buy ratings.
ATO presents a mixed outlook with solid earnings growth and dividend stability offset by bearish technical indicators and negative cash flow trends. The stock offers value through consistent profitability and infrastructure investments, though investors face risks from high capital expenditures and debt levels that could pressure future returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →
